ArticleHuman molecular genetics2019
CRISPR/Cas9-mediated disruption of SHANK3 in monkey leads to drug-treatable autism-like symptoms.
Article in Human molecular genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 71 citations in OpenAlex.
- DISC1 mutant macaques capture behavioral and neural hallmarks of psychiatric disease.National science review · 2026Article
- Primate neuroethology: a new synthesis.Trends in cognitive sciences · 2026Review
- Genetically Modified Primate Models for Brain Disorder Research.Neuroscience bulletin · 2026Review
- Unconventional Non-rodent Models in Neurological Research: Exploring New Paths to Translational Insights.Journal of molecular neuroscience : MN · 2025Review
- CRISPR-Cas-Based Diagnostics in Biomedicine: Principles, Applications, and Future Trajectories.Biosensors · 2025Review
- Review
- Autism-like atypical face processing inScience advances · 2025Article
- Establishment of a standardized daily behavior collection and analysis system for brain disease models of rhesus and cynomolgus monkeys and its application in autism spectrum disorder.Journal of Zhejiang University. Science. B · 2024Article
- Tauopathy promotes spinal cord-dependent production of toxic amyloid-beta in transgenic monkeys.Signal transduction and targeted therapy · 2023Article
- Modeling SHANK3-associated autism spectrum disorder in Beagle dogs via CRISPR/Cas9 gene editing.Molecular psychiatry · 2023Article
- Advancements in pre-clinical development of gene editing-based therapies to treat inherited retinal diseases.Vision research · 2023Article
- CATI: an efficient gene integration method for rodent and primate embryos by MMEJ suppression.Genome biology · 2023Article
- Review
- CHD8 mutations increase gliogenesis to enlarge brain size in the nonhuman primate.Cell discovery · 2023Article
- Review
- The Evolving Role of Animal Models in the Discovery and Development of Novel Treatments for Psychiatric Disorders.Advances in neurobiology · 2023Article
- Targeting Shank3 deficiency and paresthesia in autism spectrum disorder: A brief review.Frontiers in molecular neuroscience · 2023Review
- Swimming exercise is a promising early intervention for autism-like behavior in Shank3 deletion rats.CNS neuroscience & therapeutics · 2023Article
- Prefrontal circuits guiding social preference: Implications in autism spectrum disorder.Neuroscience and biobehavioral reviews · 2022Review
- CRISPR/Cas9 genome editing to create nonhuman primate models for studying stem cell therapies for HIV infection.Retrovirology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
Monogenic mutations in the SHANK3 gene, which encodes a postsynaptic scaffold protein, play a causative role in autism spectrum disorder (ASD). Although a number of mouse models with Shank3 mutations have been valuable for investigating the pathogenesis of ASD, species-dependent differences in behaviors and brain structures post considerable challenges to use small animals to model ASD and to translate experimental therapeutics to the clinic. We have used clustered regularly interspersed short palindromic repeat/CRISPR-associated nuclease 9 to generate a cynomolgus monkey model by disrupting SHANK3 at exons 6 and 12. Analysis of the live mutant monkey revealed the core behavioral abnormalities of ASD, including impaired social interaction and repetitive behaviors, and reduced brain network activities detected by positron-emission computed tomography (PET). Importantly, these abnormal behaviors and brain activities were alleviated by the antidepressant fluoxetine treatment. Our findings provide the first demonstration that the genetically modified non-human primate can be used for translational research of therapeutics for ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.